Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints

Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 3692) VOLUNTARY ANNOUNCEMENT THE PHASE III CLINICAL STUDY OF HS-10374 IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS HAS MET THE CO-PRIMARY ENDPOINTS The board of directors (the “Board”) of Hansoh Pharmaceutical Group Company Limited (the “Company” and together w